R&D

United kills its PhIII PAH drug after it fails Tyvaso combo study

Just a few weeks after Sandoz pushed out a generic version of United Therapeutics’ PAH drug Remodulin, United was forced to concede another setback for its all-important pulmonary arterial hypertension franchise. In a single sentence United $UTHR said that its Phase III study of esuberaprost combined with another one of its PAH drugs, Tyvaso, had failed to beat the branded drug alone.

They dropped the drug. That’s it. Over and out.

According to clinicaltrials.gov, the study was launched 6 years ago.

Jefferies’ Eun Yang had been fairly upbeat about the possibilities, with a better side effect profile perhaps delaying the use of Remodulin, which now has generics eating away at its peak sales figure. A success could have bumped Tyvaso use by 10%, increasing its value to the company. He figured a win or loss here was good for a 5% increase or drop in the share price depending on its success or failure. United stock was 3% in the red in early-morning trading.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->